CBP-501
Also known as: CanBas-501, CBP-501, CBP501
Source CBP-501 at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
CBP-501 (also known as CanBas‑501) is an investigational synthetic peptide being explored as a cancer‑sensitizing agent. Classified as a cell‑penetrating peptide, it is intended to enhance the response of tumor cells to anticancer therapies. The compound is currently in research use only and has been mentioned in several conference reports, but no peer‑reviewed clinical trial results have been published.
Mechanism of Action
The available abstracts describe CBP-501 simply as a cell‑penetrating peptide designed to act as a cancer sensitizer. No detailed molecular targets or pathways are provided in the cited literature; the implication is that the peptide can enter cells and potentially modulate intracellular processes to increase susceptibility to standard anticancer agents.
What the Research Shows
CBP‑501 appears in four PubMed‑indexed abstracts, all of which are conference or trial‑listing reports (2007, 2008, 2010). The 2010 AACR‑NCI‑EORTC symposium abstract lists CBP‑501 among other investigational drugs under development for cancer therapy. Earlier “Gateways to clinical trials” articles (2007, 2008) include CBP‑501 in long tables of compounds in early development, without providing efficacy, safety, or pharmacokinetic data. A 2010 Japan Biotech Forum report also mentions CBP‑501 as a licensing opportunity. No preclinical or clinical study results, dosing regimens, or outcome measures are detailed in these sources.
Reported Benefits
The principal potential benefit suggested by the limited literature is that CBP‑501 could increase the effectiveness of existing anticancer treatments by sensitising tumor cells. This concept is based on its classification as a cell‑penetrating, cancer‑sensitizing peptide, but no experimental or clinical evidence of benefit has been presented in the cited abstracts.
Limitations of the Evidence
Evidence for CBP‑501 is confined to conference listings; there are no published preclinical efficacy studies, pharmacology data, or clinical trial outcomes. The mechanism of sensitisation remains undefined, and the lack of peer‑reviewed results limits any assessment of its therapeutic value. Consequently, the current knowledge base is insufficient to support conclusions about efficacy or optimal use.
Safety Considerations
The abstracts provide no information on adverse events, toxicity, or safety monitoring for CBP‑501. Without preclinical or clinical safety data, potential risks remain unknown. Researchers considering CBP‑501 in experimental protocols should treat it as an investigational agent with undetermined safety profile and follow standard precautionary measures for novel peptides.
How It Is Administered
CBP‑501 is reported to be administered by intravenous or subcutaneous injection in research settings. No formulation details, dosing schedules, or concentration specifications are provided in the available literature.
Routes of Administration
Goals & Uses
- Sensitization to cisplatin chemotherapyOncology / ChemosensitizationModerate
- Immunogenic cell death inductionOncology / Immuno OncologyLow
- overcome drug resistanceOncologyModerate
- Treatment of malignant pleural mesotheliomaOncology / Solid TumorModerate
- G2/M checkpoint abrogation in cancer cellsOncology / Cell Cycle ModulationModerate
- enhance chemotherapy efficacyOncologyModerate
Contraindications
- Severe hepatic impairmentOrganModerateLiver function concerns
- Severe renal impairmentOrganHighKidney function concerns
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- Severe hypersensitivity to CBP-501 or excipientsAllergy / HypersensitivityHigh
Adverse Effects
- Neurotoxicity / peripheral neuropathyNeurologicalUncommon
- Infusion‑related reactionsGeneralUncommon
- Nausea and vomitingGastrointestinalCommon
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- FatigueGeneralCommonLow energy or tiredness
- MyelosuppressionHematologicCommon
- Infusion-related reactionsHypersensitivityUncommon
- NephrotoxicityRenalUncommon
Drug Interactions
- CarboplatinModerate
- PemetrexedModerate
- CisplatinModerate
- Nephrotoxic agentsHigh
Population Constraints
- Patients with pre-existing renal impairmentOrgan FunctionRelative
- Pediatric patientsAgeRelative
- Pregnant or breastfeeding womenReproductiveAbsolute
Regulatory Status
- European UnionInvestigationalEarly‑phase studies pending.
- United StatesInvestigationalPhase I/II clinical trials ongoing.
- United KingdomUnknownNo MHRA approval known; status not clearly documented in public sources.
CBP-501 has not received FDA, EMA, or any other regulatory approval. It has been evaluated in Phase I and Phase II clinical trials in the United States and Japan, primarily in combination with cisplatin.
Evidence & Sources
- Journal ArticleLowWalker K, Padhiar M2010-01-01T00:00:00.000000Z
- Journal ArticleLowTomillero A, Moral MA2008-01-01T00:00:00.000000Z
- Journal ArticleUngradedAl-Shamahi A2010-01-01T00:00:00.000000Z
- Journal ArticleLowBayes M, Rabasseda X, Prous JR2007-01-01T00:00:00.000000Z
Frequently Asked Questions
What type of molecule is CBP‑501?
CBP‑501 is a synthetic, cell‑penetrating peptide that is being investigated as a cancer‑sensitizing agent. It belongs to the class of investigational peptides designed to enhance the effect of other anticancer drugs.
Has CBP‑501 been tested in humans?
The cited abstracts only mention CBP‑501 in conference presentations and trial‑listing articles. No published clinical trial results or human study data are provided, so its testing in patients has not been documented in the available literature.
What is known about how CBP‑501 works?
The literature describes CBP‑501 simply as a cell‑penetrating peptide intended to sensitize cancer cells, but it does not detail specific molecular targets, pathways, or mechanisms by which it might enhance therapy.
Are there any safety concerns reported for CBP‑501?
No safety or toxicity information is reported in the available abstracts. Without preclinical or clinical data, potential adverse effects remain unknown.
How is CBP‑501 administered in research?
Research reports list intravenous and subcutaneous injection as the routes of administration for CBP‑501. Specific formulation or dosing details have not been disclosed in the cited sources.
What is CBP-501 used for?
CBP-501 is educationally associated with: Sensitization to cisplatin chemotherapy, Immunogenic cell death induction, overcome drug resistance, Treatment of malignant pleural mesothelioma, G2/M checkpoint abrogation in cancer cells, enhance chemotherapy efficacy. Educational only — not medical advice.
How is CBP-501 administered?
Recorded routes of administration: Intravenous, Subcutaneous.
What are the potential side effects of CBP-501?
Reported adverse effects include: Neurotoxicity / peripheral neuropathy, Infusion‑related reactions, Nausea and vomiting, Nausea, Fatigue, Myelosuppression, Infusion-related reactions, Nephrotoxicity. This list is not exhaustive — consult a qualified clinician.
Who should avoid CBP-501?
Recorded contraindications: Severe hepatic impairment, Severe renal impairment, Pregnancy, Severe hypersensitivity to CBP-501 or excipients. Consult a qualified clinician before use.